Refine by
Laparoscopic System Articles & Analysis: Older
17 news found
The FDA-approved ReShape® Integrated Dual Balloon System involves a non-surgical weight loss procedure that uses advanced interconnected balloon technology designed to take up room in the stomach to help people with a 30-40 BMI, and at least one co-morbidity, lose weight. vBloc® Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like device called the vBloc ...
New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric Banding Company to Introduce Product at IFSO 2022 World Congress in August; Sales to Commence in September ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions ...
The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps ...
There are two aspects of this project: (l)The development of a robotic platform for laparoscopic surgery that addresses the limitations of current robotic laparoscopic surgery systems available on the market, and (2) the development of a teleoperated robotic platform for reconstructive microsurgery, consisting of robotic micro-instruments with ...
Sanders and her colleagues conducted a variety of procedures using the ActivSight imaging module on patients undergoing elective laparoscopic and robotic-assisted bariatric and colorectal anastomoses and cholecystectomies with the goal of improving patient safety by reducing adverse complications through augmented visual intelligence. The imaging module is an easy-to-adapt ...
” Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. ...
With features such as precise real-time intraoperative measurements and digital tags, the ISU’s intraoperative intelligence sets Senhance apart from other current and future robotic systems.” Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages ...
” Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. ...
(NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced Hirosaki University Hospital has entered into an agreement to lease and utilize a Senhance® Surgical System. “We are excited to add a system at Hirosaki ...
With a dedicated training center and a growing number of active systems at prestigious institutions, we expect to further accelerate adoption in the region in the future.’’ Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to ...
Food and Drug Administration for its VisionPort™ System. The VisionPort™ imaging and access system simplifies laparoscopic procedures for hospitals and provides surgeon-controlled visualization. Its dual-camera design offers multiple, simultaneous views of the anatomy and surgical instrumentation – unavailable with conventional ...
Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. ...
Patent Number 10010441 entitled “Gastric Restriction Device for Treating Obesity,” which covers a patent application regarding the Company’s Gastric Vest System (the “ReShape Vest”). Barring any unforeseen circumstances, this patent will be valid until December 5, 2028. ...
The FDA-approved ReShape Balloon System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 Body BMI and at least one co-morbidity lose weight. ReShape vBloc™ Therapy, delivered by an FDA-approved pacemaker-like device called the ReShape vBloc System, is ...
The FDA-approved ReShape® Balloon involves a non-surgical weight loss procedure that uses advanced interconnected balloon technology designed to take up room in the stomach to help people with a 30-40 Body Mass Index (BMI), and at least one co-morbidity, feel full and lose weight. vBloc® Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like device called the vBloc ...
This order, the second since Al Zawhari’s initial stocking order in August 2017, is to support increased demand for the Reshape Integrated Dual Balloon System from a leading hospital customer’s growing bariatric program in Dubai. ...
Dr. Iannitti (Carolinas Health System) presented Aim for Stapler and Vessel Sealer Navigation at the http://www.ills2017.com/ 2017 Conference. In his talk, titled "Image guidance system for laparoscopic ablation and resection," Dr. Iannitti described how stapler and vessel sealer navigation can make laparoscopic liver surgery ...